Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631289 | 0.83 | ALDH1A1 (0.32) | RECQLALDH1A1 | |
| SCHEMBL27598235 | 0.83 | CYP3A4 (0.35) | CYP3A4ALDH1A1 | |
| SCHEMBL29117785 | 0.83 | CYP3A4 (0.35) | CYP3A4ALDH1A1 | |
| SCHEMBL13901492 | 0.83 | ALDH1A1 (0.40) | RECQLCYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL10456332 | 0.80 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL28493598 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL11017016 | 0.74 | RECQL (0.31) | RECQL | |
| SCHEMBL13901348 | 0.73 | — | — | |
| SCHEMBL3883609 | 0.70 | HCAR2 (0.43) | RECQLCYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL17518654 | 0.70 | HCAR2 (0.43) | RECQLCYP3A4CYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | RECQL 4442/4885CYP3A4 2468/4885CYP2C9 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.